Compare BNRG & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNRG | GNPX |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.2M |
| IPO Year | 2022 | 2018 |
| Metric | BNRG | GNPX |
|---|---|---|
| Price | $0.82 | $1.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 134.3K | ★ 274.0K |
| Earning Date | 09-30-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $387,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 843.90 | N/A |
| 52 Week Low | $0.61 | $1.75 |
| 52 Week High | $15.30 | $55.00 |
| Indicator | BNRG | GNPX |
|---|---|---|
| Relative Strength Index (RSI) | 42.76 | 30.92 |
| Support Level | $0.63 | $2.51 |
| Resistance Level | $0.93 | $3.68 |
| Average True Range (ATR) | 0.10 | 0.22 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 41.05 | 2.93 |
Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.